Professional Documents
Culture Documents
Introduction
In the golden age of the discovery of antibiotics,
innumerable lives were saved. These highly potent
miracle drugs are no longer as effective as they were
a half a century ago [1]. We are now entering an era in
which bacterial infections, such as septicemia and
ventilator-associated pneumonia, might no longer be
successfully treated with antibiotics [1]. A few years
ago, New Yorker magazine aptly satirized American
attitudes toward antibiotics with a cartoon of a doctor's
office sign: Don't forget to take a handful of our
complimentary antibiotics on your way out.
Antibiotics resistance in United States
In 2008, the Infectious Disease Society of America
(IDSA) confirmed that the United States and the rest
of the world are in the midst of an emerging crisis of
antibiotic resistance for microbial pathogens [2].
Antibiotic resistance is fueled by misuse and overuse
of antibiotics. Bacteria become resistant to the very
medicine developed to treat and cure the infections
they cause. Epidemic antibiotic resistance has been
described in numerous pathogens in varying contexts,
including, but not limited to, a global pandemic of
methicillin-resistant Staphylococcus aureus (MRSA)
infection [3], vancomycin-resistant enterococci (VRE),
and a growing number of additional pathogens that are
developing resistance to many common antibiotics.
130
134
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
18. Filice GA, Nyman JA, Lexau C (2010) Excess costs and
utilization associated with methicillin resistance for patients
with Staphylococcus aureus infection. Infect Control Hosp
Epidemiol 31: 365-367.
19. Facts about Antibiotic Resistance (2012) Infectious Diseases
Society
of
America.
Available
at:
http://www.idsociety.org/AR_Facts. Accessed on December
12, 2012.
20. Infectious Diseases Society of America( IDSA)- (2011). Facts
about
Antibiotic
Resistance.
Availble
at
:
http://www.idsociety.org/AR_Facts/ Accessed on April 5,
2011.
21. Pear R (2011) Health Official Takes Parting Shot at Waste
By Key Obama Health Official. New York Times. Available:
http://www.nytimes.com/2011/12/04/health/policy/partingshot-at-waste-by-key-obama-health-official.html?_r=1&.
Accessed 20 December 2012.
22. Spellberg B, Powers JH, Brass EP, Miller LG, Edwards JE
(2008) The Epidemic of Antibiotic-Resistant Infections:A
Call to Action for the Medical Community from the
Infectious Diseases Society of America. Clinical Infectious
Diseases 46: 155-164.
23. Dellit TH, Owens RC, McGowan JE, Gerding DN, Weinstein
RA, Burke JP, Huskins WC, Paterson DL, Fishman NO,
Carpenter CF, Brennan PJ, Billeter M, Hooton TM (2007)
Infectious Diseases Society of America and the Society for
Healthcare Epidemiology of America guidelines for
developing an institutional program to enhance antimicrobial
stewardship. Clin Infect Dis 44: 159-177.
24. Infectious Diseases Society of America (2004) Bad bugs, no
drugs: as antibiotic discovery stagnates, a public health crisis
brews. Available: www.fda.gov/ohrms/dockets/.../04s-0233c000005-03-IDSA-vol 1.pdf n sssse cA ,20 December
2012
25. Nakai M, Park T, Nakai SC (2002) Park Bacteriophage
therapy of infectious diseases in aquaculture. Res. Microbiol
153: 13-18.
26. Cerveny KA, DePaola A, Duckworth DH, Gulig PA (2002)
Phage therapy of local and systemic disease caused by Vibrio
vulnificus in iron-dextran-treated mice. Infect. Immun 70:
6251-6262.
27. Keen EC (2012) Felix dHerelle and Our Microbial Future.
Future Microbiology 7: 1337-1339.
28. Adhya S, Merril C (2006) The road to phage therapy. Nature
443: 754-755.
29. Duckworth DH (1976) Who discovered bacteriophage?
Bacteriol Rev 40: 793-802.
30. Kuchment A (2012) The Forgotten Cure: The Past and Future
of Phage Therapy. Springer, New York. 170 p.
31. Ho K (2001) Bacteriophage therapy for bacterial infections:
rekindling a memory. Perspect Biol Med 44: 1-16.
32. Sulakvelidze A, Alavidze Z, Morris GJ (2001) Antimicrob
Agents Chemother 45: 649-659.
33. Weber-Dabrowska B, Mulczyk M, Gorski A (2000)
Bacteriophage therapy of bacterial infections: an update of
our institute's experience. Arch Immunol Ther Exp (Warsz)
48: 547-551.
34. Matsuzaki S, Rashel M, Uchiyama J, Sakurai S, Ujihara T,
Kuroda M, Ikeuchi M, Tani T, Fujieda M, Wakiguchi H, Imai
S (2005) Bacteriophage therapy: a revitalized therapy against
bacterial infectious diseases. J Infect Chemother 11: 211-219.
135
53.
54.
55.
56.
57.
58.
59.
60.
61.
62.
63.
Corresponding author
Zhabiz Golkar, PhD
South Carolina Center for Biotechnology
Claflin University
400 Magnolia Street
Orangeburg, SC 29115, USA
Phone: (803) 535-5502
Fax: (803) 535-5776
Email: zgolkar@claflin.edu,
Email: zhabizg@yahoo.com
136